The 4 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 24.50, with a high estimate of 27.00 and a low estimate of 22.00. The median estimate represents a +207.02% increase from the last price of 7.98.
The current consensus among 4 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.34
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.